SEARCH

SEARCH BY CITATION

References

  • 1
    Pixley FJ & Stanley ER (2004) CSF-1 regulation of the wandering macrophage: complexity in action. Trends Cell Biol 14, 628638.
  • 2
    Mouchemore KA & Pixley FJ (2012) CSF-1 signaling in macrophages: pleiotrophy through phosphotyrosine-based signaling pathways. Crit Rev Clin Lab Sci 49, 4961.
  • 3
    Pollard JW (2009) Trophic macrophages in development and disease. Nat Rev Immunol 9, 259270.
  • 4
    Hamilton JA (2008) Colony-stimulating factors in inflammation and autoimmunity. Nat Rev Immunol 8, 533544.
  • 5
    Pixley FJ (2012) Macrophage migration and its regulation by CSF-1. Int J Cell Biol 2012, doi: 10.1155/2012/501962.
  • 6
    Stanley ER & Heard PM (1977) Factors regulating macrophage production and growth. Purification and some properties of the colony stimulating factor from medium conditioned by mouse L cells. J Biol Chem 252, 43054312.
  • 7
    Wang JM, Griffin JD, Rambaldi A, Chen ZG & Mantovani A (1988) Induction of monocyte migration by recombinant macrophage colony-stimulating factor. J Immunol 141, 575579.
  • 8
    Scholl SM, Bascou CH, Mosseri V, Olivares R, Magdelenat H, Dorval T, Palangie T, Validire P, Pouillart P & Stanley ER (1994) Circulating levels of colony-stimulating factor 1 as a prognostic indicator in 82 patients with epithelial ovarian cancer. Br J Cancer 69, 342346.
  • 9
    Kacinski BM (1997) CSF-1 and its receptor in breast carcinomas and neoplasms of the female reproductive tract. Mol Reprod Dev 46, 7174.
  • 10
    McDermott RS, Deneux L, Mosseri V, Vedrenne J, Clough K, Fourquet A, Rodriguez J, Cosset JM, Sastre X, Beuzeboc P et al. (2002) Circulating macrophage colony stimulating factor as a marker of tumour progression. Eur Cytokine Netw 13, 121127.
  • 11
    Scholl SM, Pallud C, Beuvon F, Hacene K, Stanley ER, Rohrschneider L, Tang R, Pouillart P & Lidereau R (1994) Anti-colony-stimulating factor-1 antibody staining in primary breast adenocarcinomas correlates with marked inflammatory cell infiltrates and prognosis. J Natl Cancer Inst 86, 120126.
  • 12
    Lin EY, Nguyen AV, Russell RG & Pollard JW (2001) Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J Exp Med 193, 727740.
  • 13
    Wyckoff J, Wang W, Lin EY, Wang Y, Pixley F, Stanley ER, Graf T, Pollard JW, Segall J & Condeelis J (2004) A paracrine loop between tumor cells and macrophages is required for tumor cell migration in mammary tumors. Cancer Res 64, 70227029.
  • 14
    Goswami S, Sahai E, Wyckoff JB, Cammer M, Cox D, PIxley FJ, Stanley ER, Segall JE & Condeelis JS (2005) Macrophages promote the invasion of breast carcinoma cells via a colony-stimulating factor-1/epidermal growth factor paracrine loop. Cancer Res 65, 52785283.
  • 15
    Roussos ET, Balsamo M, Alford SK, Wyckoff JB, Gligorijevic B, Wang Y, Pozzuto M, Stobezki R, Goswami S, Segall JE et al. (2011) Mena invasive (MenaINV) promotes multicellular streaming motility and transendothelial migration in a mouse model of breast cancer. J Cell Sci 124, 21202131.
  • 16
    Yu W, Chen J, Xiong Y, Pixley FJ, Dai XM, Yeung YG & Stanley ER (2008) CSF-1 receptor structure/function in MacCsf1r–/– macrophages: regulation of proliferation, differentiation, and morphology. J Leukoc Biol 84, 852863.
  • 17
    Sampaio NG, Yu W, Cox D, Wyckoff J, Condeelis J, Stanley ER & Pixley FJ (2011) Phosphorylation of CSF-1R Y721 mediates its association with PI3K to regulate macrophage motility and enhancement of tumor cell invasion. J Cell Sci 124, 20212031.
  • 18
    Vanhaesebroeck B, Guillermet-Guibert J, Graupera M & Bilanges B (2010) The emerging mechanisms of isoform-specific PI3K signalling. Nat Rev Mol Cell Biol 11, 329341.
  • 19
    Wu H, Yan Y & Backer JM (2007) Regulation of class IA PI3Ks. Biochem Soc Trans 35, 242244.
  • 20
    Papakonstanti EA, Zwaenepoel O, Bilancio A, Burns E, Nock GE, Houseman B, Shokat K, Ridley AJ & Vanhaesebroeck B (2008) Distinct roles of class IA PI3K isoforms in primary and immortalised macrophages. J Cell Sci 121, 41244133.
  • 21
    Lannutti BJ, Meadows SA, Herman SE, Kashishian A, Steiner B, Johnson AJ, Byrd JC, Tyner JW, Loriaux MM, Deininger M et al. (2011) CAL-101, a p110δ selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood 117, 591594.
  • 22
    Hoellenriegel J, Meadows SA, Sivina M, Wierda WG, Kantarjian H, Keating MJ, Giese N, O'Brien S, Yu A, Miller LL et al. (2011) The phosphoinositide 3′-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Blood 118, 36033612.
  • 23
    Burger JA (2012) Targeting the microenvironment in chronic lymphocytic leukemia is changing the therapeutic landscape. Curr Opin Oncol 24, 643649.
  • 24
    Faccio R, Takeshita S, Colaianni G, Chappel J, Zallone A, Teitelbaum SL & Ross FP (2007) M-CSF regulates the cytoskeleton via recruitment of a multimeric signaling complex to c–Fms Tyr–559/697/721. J Biol Chem 282, 1899118999.
  • 25
    Vanhaesebroeck B, Jones GE, Allen WE, Zicha D, Hooshmand-Rad R, Sawyer C, Wells C, Waterfield MD & Ridley AJ (1999) Distinct PI(3)Ks mediate mitogenic signalling and cell migration in macrophages. Nat Cell Biol 1, 6971.
  • 26
    Ikeda H, Hideshima T, Fulciniti M, Perrone G, Miura N, Yasui H, Okawa Y, Kiziltepe T, Santo L, Vallet S et al. (2010) PI3K/p110δ is a novel therapeutic target in multiple myeloma. Blood 116, 14601468.
  • 27
    Bingle L, Brown NJ & Lewis CE (2002) The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol 196, 254265.
  • 28
    Aharinejad S, Paulus P, Sioud M, Hofmann M, Zins K, Schafer R, Stanley ER & Abraham D (2004) Colony-stimulating factor-1 blockade by antisense oligonucleotides and small interfering RNAs suppresses growth of human mammary tumor xenografts in mice. Cancer Res 64, 53785384.
  • 29
    Lin EY & Pollard JW (2007) Tumor-associated macrophages press the angiogenic switch in breast cancer. Cancer Res 67, 50645066.
  • 30
    Jeon BH, Jang C, Han J, Kataru RP, Piao L, Jung K, Cha HJ, Schwendener RA, Jang KY, Kim KS et al. (2008) Profound but dysfunctional lymphangiogenesis via vascular endothelial growth factor ligands from CD11b+ macrophages in advanced ovarian cancer. Cancer Res 68, 11001109.
  • 31
    Coffelt SB, Hughes R & Lewis CE (2009) Tumor-associated macrophages: effectors of angiogenesis and tumor progression. Biochim Biophys Acta 1796, 1118.
  • 32
    Xue C, Wyckoff J, Liang F, Sidani M, Violini S, Tsai KL, Zhang ZY, Sahai E, Condeelis J & Segall JE (2006) Epidermal growth factor receptor overexpression results in increased tumor cell motility in vivo coordinately with enhanced intravasation and metastasis. Cancer Res 66, 192197.
  • 33
    Meadows SA, Vega F, Kashishian A, Johnson D, Diehl V, Miller LL, Younes A & Lannutti BJ (2012) PI3Kδ inhibitor, GS-1101 (CAL-101), attenuates pathway signaling, induces apoptosis, and overcomes signals from the microenvironment in cellular models of Hodgkin lymphoma. Blood 119, 18971900.
  • 34
    Davids MS, Deng J, Wiestner A, Lannutti BJ, Wang L, Wu CJ, Wilson WH, Brown JR & Letai A (2012) Decreased mitochondrial apoptotic priming underlies stroma-mediated treatment resistance in chronic lymphocytic leukemia. Blood 120, 35013509.
  • 35
    Pixley FJ, Xiong Y, Yu RY, Sahai EA, Stanley ER & Ye BH (2005) BCL6 suppresses RhoA activity to alter macrophage morphology and motility. J Cell Sci 118, 18731883.